Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box DNA helicase 1 (FBH1) is a unique bifunctional DNA helicase and F-box protein characterized by its DNA-dependent ATPase and 3'-5' DNA unwinding activities, as well as its role as a component of the SKP1–CUL1–F-box (SCF) E3 ubiquitin ligase complex[1][2][5]. FBH1 regulates homologous recombination by targeting and promoting the dissolution of RAD51 filaments at stalled DNA replication forks, thereby restricting hyper-recombination and preventing chromosomal instability[1][2][3][5]. As part of the cellular response to replication stress, FBH1 can promote double-strand break formation in concert with other nucleases like MUS81 and can trigger apoptosis in cells with severe replication stress, providing a tumor suppressor-like function[1][2][3]. FBH1 mutations or loss have been linked to a higher frequency of DNA repair defects, genomic instability, and increased cancer risk, including associations with certain melanomas and cancer predisposition syndromes[1][3][5]. No currently available drugs are known to act directly on FBH1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box DNA helicase 1 (FBH1).